The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor
Abstract
The use of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors, statins, has been shown to reduce major cardiovascular events in both primary and secondary prevention, and statins became one of the most widely prescribed classes of drugs throughout the world. Previously, statins have been well tolerated and have shown favorable safety profiles. However, the voluntary withdrawal of cerivastatin from the market because of a disproportionate number of reports of rhabdomyolysis‐associated deaths drew attention to the pharmacokinetic profile of statins, which may possibly have been related to serious drug‐drug interactions. Pitavastatin (NK‐104, previously called itavastatin or nisvastatin, Kowa Company Ltd., Tokyo) is a novel, fully synthetic statin, which has a potent cholesterol‐lowering action. The short‐term and long‐term lipid‐modifying effects of pitavastatin have already been investigated in subjects with primary hypercholesterolemia, heterozygous familial hypercholesterolemia, hypertriglyceridemia, and type‐2 diabetes mellitus accompanied by hyperlipidemia. Within the range of daily doses from 1 to 4 mg, the efficacy of pitavastatin as a lipid‐lowering drug seems to be similar, or potentially superior, to that of atorvastatin. According to the results of pharmacokinetic studies, pitavastatin showed favorable and promising safety profile; it was only slightly metabolized by the cytochrome P450 (CYP) system, its lactone form had no inhibitory effects on the CYP3A4‐mediated metabolism of concomitantly administered drugs; P‐glycoprotein‐mediated transport did not play a major role in its disposition, and pitavastatin did not inhibit P‐glycoprotein activity. It could be concluded that pitavastatin could provide a new and potentially better thera‐peutic choice for lipid‐modifying therapy than do the currently available statins. The ef‐ficacy and safety of higher dose treatment, as well as its long‐term effects in the pre‐vention of coronary artery disease, should be further investigated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Statins are not applicable as single antifungal agents for the treatment of IFI because their MICs are much higher (about 1 order of magnitude) than their maximum achievable concentrations in human serum [11,[40][41][42][43][44][45] .”
From Statins as antifungal agents (2011) · cites this paper as [40]
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Research works printed but not linked: 6
- FujinoH ShimadaS YamadaI TsunenariY HiranoM KojimaJ.Interaction between fibrates and statins. In:Abstract of 13th International conference on cytochromes P450 2003(in Czech).
- Nakaya N, 2001, A Phase 1 clinical study of a novel HMG‐CoA reductase inhibitor, NK‐104 (pitavastatin). Results of single and 7‐day repeated oral administration studies in healthy adult male volunteers, J Clin Ther Med, 17, 741
- Nakaya N, 2001, Efficacy and safety of NK‐104 (pitavastatin), a novel HMG‐CoA reductase inhibitor in hypercholesterolemic volunteers, J Clin Ther Med, 17, 767
- Nakaya N, 2001, Pharmacokinetics of repeated Dose NK‐104 (pitavastatin), in healthy elderly and non‐elderly volunteers, J Clin Ther Med, 17, 957
- Ouchi Y, 2001, Efficacy and safety of NK‐104 (pitavastatin), a new HMG‐CoA reductase inhibitor in the elderly patients with hyperlipidemia, Geriatr Med, 39, 849
- Shimada Y, 1996, Partition coefficient and hepatic cell‐selectivity of HMG‐CoA Reductase inhibitors, Progr Med, 18, 957
Cited by
Sorted by citations
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,086
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 496
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068056 · Cited by 444
“Pitavastatin is a highly potent inhibitor of 3-hydroxy-3methylglutaryl (HMG)-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis (Aoki et al., 1997; Kajinami et al., 2003).”
InfluentialWiggins, B. S., Saseen, J. J., Page, R. L., II, Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D. E., Virani, S. S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 345
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009290 · Cited by 302
“Pitavastatin is a highly potent inhibitor of HMG-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis (Aoki et al., 1997; Kajinami et al., 2003).”
Background
Metadata
- Authors
- Kajinami, K., Takekoshi, N., & Saito, Y.
- Affiliations
- Kanazawa Medical University (JP)
- Chiba University (JP)
- Corresponding author
- Kajinami, Kouji
- ORCID
- Saito, Yasushi
- Venue
- Cardiovascular Drug Reviews
- Publisher
- Wiley
- Published
- 2003-09
- Volume
- 21
- Issue
- 3
- Pages
- 199-215
- ISSN
- 0897-5957 (ISSN-L)
- 1527-3466
- OpenAlex
- W2074541010
- Cited by
- 136
- References
- 77
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 8 · 2021: 8 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 5 · 2016: 6 · 2015: 3 · 2014: 6 · 2013: 4 · 2012: 2
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cardiovascular Drug Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- pitavastatin, statins, lipid-lowering therapy, hypercholesterolemia, familial hypercholesterolemia, hypertriglyceridemia, type 2 diabetes, pharmacokinetics, drug-drug interactions, cytochrome P450, P-glycoprotein, rhabdomyolysis, atorvastatin comparison, coronary heart disease prevention
- MeSH terms
- Animals, Arteriosclerosis, Clinical Trials as Topic, Cytochrome P-450 Enzyme System, Drug Interactions, Humans, Hypercholesterolemia, Lipoproteins, Quinolines, Hydroxymethylglutaryl-CoA Reductase Inhibitors, ATP Binding Cassette Transporter, Subfamily B, Member 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
